tiprankstipranks
Trending News
More News >
Colgate-Palmolive (India) Limited (IN:COLPAL)
:COLPAL
India Market

Colgate-Palmolive (India) Limited (COLPAL) AI Stock Analysis

Compare
8 Followers

Top Page

IN:COLPAL

Colgate-Palmolive (India) Limited

(COLPAL)

Select Model
Select Model
Select Model
Outperform 70 (OpenAI - 5.2)
,
Outperform 70 (OpenAI - 5.2)
,
Outperform 70 (OpenAI - 5.2)
,
Outperform 70 (OpenAI - 5.2)
,
Outperform 70 (OpenAI - 5.2)
,
Outperform 70 (OpenAI - 5.2)
,
Outperform 70 (OpenAI - 5.2)
,
Outperform 70 (OpenAI - 5.2)
,
Outperform 70 (OpenAI - 5.2)
Rating:70Outperform
Price Target:
₹2,126.00
▲(2.36% Upside)
Action:UpgradedDate:11/01/25
Colgate-Palmolive (India) Limited's strong financial performance is the most significant factor, showcasing robust revenue growth and profitability. However, technical indicators suggest potential bearish momentum, and the high P/E ratio indicates a relatively expensive valuation. The absence of earnings call data and corporate events limits further insights.
Positive Factors
High Profitability
Sustained double-digit operating and net margins indicate structural pricing power and cost efficiency from scale and brand premium in oral-care. High gross margins provide durable buffer versus input inflation and fund marketing, R&D and returns to shareholders over the medium term.
Strong Balance Sheet
Very low leverage and a strong equity ratio reduce financial vulnerability, enabling steady investment in distribution, manufacturing and innovation without refinancing risk. This structural strength supports resilience through cycles and strategic flexibility for capex or M&A.
Robust Cash Generation
High cash conversion and near-par conversion of accounting profit to operating cash, plus solid FCF growth, underpin sustainable funding for marketing, productivity programs and dividends. Durable cash flow supports reinvestment and cushions against short-term demand swings.
Negative Factors
Recent Revenue Weakness
Trailing decline in reported revenue growth suggests emerging pressure on volumes or price mix. If persistent, slower top-line expansion constrains the company’s ability to scale fixed-cost leverage, limits reinvestment capacity and could pressure long-term margin trajectories.
EPS Contraction
Negative EPS growth indicates profitability pressure beyond one-off items, which may reflect rising costs, mix shifts or slower resale volumes. Continued EPS decline would reduce free cash available for dividends and strategic initiatives and weaken shareholder return prospects.
Concentration in Oral Care
Heavy reliance on a single high-frequency category leaves the business exposed to category saturation, intensified competition or shifts in consumer habits. Limited diversification raises the strategic risk that oral-care growth slows and constrains long-term top-line optionality.

Colgate-Palmolive (India) Limited (COLPAL) vs. iShares MSCI India ETF (INDA)

Colgate-Palmolive (India) Limited Business Overview & Revenue Model

Company DescriptionColgate-Palmolive (India) Limited manufactures and trades in personal and oral care products in India. The company offers toothpastes, toothpowder, toothbrushes, oil pulling products, mouthwashes, and dental gels, as well as specialty products under the Colgate brand name. It also provides soaps, cosmetics, and toilet preparations. The company offers a range of personal care products, such as shower gels and liquid hand washes under the Palmolive brand name. It also exports its products. The company was incorporated in 1937 and is headquartered in Mumbai, India.
How the Company Makes MoneyColgate-Palmolive (India) Limited primarily makes money by selling branded consumer products in India, with revenue recognized from the sale of finished goods to a broad base of trade customers (distributors/wholesalers and retailers), modern trade accounts, and online channels, which then sell onward to end consumers. The largest revenue stream is typically oral care: toothpaste (a high-frequency replenishment category) and toothbrushes (a repeat-purchase category), supported by brand-led pricing, product mix (different price tiers/pack sizes), and continuous marketing that helps sustain volume and market share. The company’s earnings are driven by (1) volume growth through household penetration and repeat purchases, (2) pricing and premiumization (introducing higher-value variants and maintaining a portfolio across value to premium price points), and (3) distribution reach and execution across urban and rural markets. Profitability depends on gross margin management—especially procurement costs for key raw/packaging materials, manufacturing efficiency, and supply-chain productivity—along with disciplined spending on advertising and consumer promotions to support brand equity and demand. Any other income streams (if present in reported financials) would generally be ancillary compared with product sales; if specific contributions from such items are not publicly detailed, they cannot be reliably quantified here and are therefore null.

Colgate-Palmolive (India) Limited Financial Statement Overview

Summary
Colgate-Palmolive (India) Limited exhibits robust financial health with strong revenue growth and high profitability margins. The company maintains minimal reliance on debt and demonstrates solid cash flow generation, supporting future expansion and investment.
Income Statement
85
Very Positive
Colgate-Palmolive (India) Limited shows strong performance with consistent revenue growth, evidenced by a Revenue Growth Rate of 6.33% in the latest year. The company maintains high profitability with a Gross Profit Margin of 69.89% and a Net Profit Margin of 23.78% for 2025. EBIT and EBITDA margins are robust at 48.87% and 32.42%, respectively, indicating efficient operations.
Balance Sheet
78
Positive
The balance sheet reflects solid equity strength with an Equity Ratio of 55.12% in 2025. The Debt-to-Equity Ratio is low at 0.037, indicating minimal leverage, which reduces financial risk. However, the Return on Equity is moderate at 86.31%, suggesting opportunities to enhance shareholder returns.
Cash Flow
80
Positive
The company demonstrates solid cash flow with a Free Cash Flow to Net Income Ratio of 0.92 for 2025, showing strong cash generation relative to profit. The Operating Cash Flow to Net Income Ratio is 0.97, indicating efficient conversion of profits into cash. Free Cash Flow Growth Rate is healthy at 17.78%, supporting further investment capabilities.
BreakdownTTMMar 2025Mar 2024Mar 2023Mar 2022Mar 2021
Income Statement
Total Revenue58.55B60.40B56.80B52.26B50.95B48.38B
Gross Profit39.20B42.22B30.85B26.08B31.10B24.94B
EBITDA19.26B19.58B19.58B15.89B15.92B15.40B
Net Income13.26B14.37B13.24B10.47B10.78B10.35B
Balance Sheet
Total Assets31.78B30.19B31.97B28.83B29.02B28.94B
Cash, Cash Equivalents and Short-Term Investments13.47B6.68B8.89B8.06B7.24B2.97B
Total Debt1.06B608.40M717.49M689.60M830.54M911.75M
Total Liabilities15.95B13.54B13.22B11.67B11.67B17.28B
Stockholders Equity15.82B16.64B18.74B17.16B17.35B11.66B
Cash Flow
Free Cash Flow9.61B13.23B11.23B11.06B15.76B7.26B
Operating Cash Flow9.97B13.94B11.99B11.76B16.26B7.84B
Investing Cash Flow3.81B559.70M792.39M-75.40M-1.08B713.53M
Financing Cash Flow-7.40B-16.71B-11.95B-10.87B-10.91B-9.56B

Colgate-Palmolive (India) Limited Technical Analysis

Technical Analysis Sentiment
Negative
Last Price2077.00
Price Trends
50DMA
2136.29
Negative
100DMA
2149.00
Negative
200DMA
2231.06
Negative
Market Momentum
MACD
-39.71
Positive
RSI
29.89
Positive
STOCH
3.95
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:COLPAL, the sentiment is Negative. The current price of 2077 is below the 20-day moving average (MA) of 2158.37, below the 50-day MA of 2136.29, and below the 200-day MA of 2231.06, indicating a bearish trend. The MACD of -39.71 indicates Positive momentum. The RSI at 29.89 is Positive, neither overbought nor oversold. The STOCH value of 3.95 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:COLPAL.

Colgate-Palmolive (India) Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (62)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
70
Outperform
₹525.71B43.582.42%-2.06%-9.74%
69
Neutral
₹980.29B54.571.42%22.56%4.73%
67
Neutral
₹5.07T20.591.84%2.94%6.05%
66
Neutral
₹802.59B39.881.62%2.68%1.07%
63
Neutral
₹324.72B54.702.08%8.28%11.65%
62
Neutral
$20.33B14.63-3.31%3.23%1.93%-12.26%
59
Neutral
₹1.07T62.791.67%5.77%
* Consumer Defensive Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IN:COLPAL
Colgate-Palmolive (India) Limited
1,932.85
-445.74
-18.74%
IN:DABUR
Dabur India Limited
452.50
-39.04
-7.94%
IN:GODREJCP
Godrej Consumer Products Limited
1,041.25
-24.57
-2.31%
IN:HINDUNILVR
Hindustan Unilever Limited
2,158.50
30.26
1.42%
IN:MARICO
Marico Limited
755.15
139.59
22.68%
IN:PGHH
Procter & Gamble Hygiene & Health Care Ltd.
10,003.45
-3,225.23
-24.38%

Colgate-Palmolive (India) Limited Corporate Events

Colgate-Palmolive, Haryana Government Tie Up to Deliver Oral Health Education to 5.7 Million Students
Feb 23, 2026

Colgate-Palmolive (India) Limited has partnered with the Government of Haryana to expand its Bright Smiles, Bright Futures oral health education initiative to 5.7 million schoolchildren across the state. The program, which already reaches more than 10 million children annually in India, will be embedded into both public and private school systems in Haryana to strengthen awareness and preventive oral hygiene practices.

The collaboration is positioned as a systemic shift from one-off awareness efforts to sustained, curriculum-linked action designed to shape lifelong habits during children’s formative years. By integrating oral health education into existing educational infrastructure, Colgate and the state government aim to deliver long-term public health benefits, bolster children’s confidence and development, and reinforce Colgate’s role as a key partner in oral health promotion at scale.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Nov 01, 2025